Your shopping cart is currently empty

ERDRP-0519 is an orally bioavailable small-molecule inhibitor of the Measles virus (MeV) polymerase. It effectively prevents measles disease in squirrel monkeys (Saimiri sciureus) and exhibits potent inhibition of morbilliviruses in the nanomolar range.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $139 | In Stock | In Stock | |
| 5 mg | $347 | In Stock | In Stock | |
| 10 mg | $488 | In Stock | In Stock | |
| 25 mg | $785 | In Stock | In Stock | |
| 50 mg | $1,120 | - | In Stock | |
| 100 mg | $1,480 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $382 | In Stock | In Stock |
| Description | ERDRP-0519 is an orally bioavailable small-molecule inhibitor of the Measles virus (MeV) polymerase. It effectively prevents measles disease in squirrel monkeys (Saimiri sciureus) and exhibits potent inhibition of morbilliviruses in the nanomolar range. |
| In vitro | ERDRP-0519 demonstrates potency against various Measles virus (MeV) isolates, with EC50 values ranging from 0.07 to 0.3 µM[1], and is also effective against MeV and related Morbillivirus pathogens, such as canine distemper virus (CDV)[3]. |
| In vivo | A single-dose pharmacokinetic study was conducted in squirrel monkeys through oral administration of ERDRP-0519 at a dose of 50 mg/kg, with blood samples collected at seven predetermined time points following the dose. The peak serum concentrations of ERDRP-0519 were observed approximately 2 hours post-administration, reaching a maximum (Cmax) of 3.27 µM. |
| Synonyms | ERDRP0519, ERDRP 0519 |
| Molecular Weight | 529.58 |
| Formula | C23H30F3N5O4S |
| Cas No. | 1374006-96-8 |
| Smiles | Cn1nc(cc1C(=O)Nc1ccc(cc1)S(=O)(=O)N1CCCC[C@H]1CCN1CCOCC1)C(F)(F)F |
| Relative Density. | 1.44 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (169.95 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.23 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.